Display options
Share it on

Urologe A. 2013 Aug;52(8):1080-3. doi: 10.1007/s00120-013-3144-2.

[Randomized controlled trials terminated prematurely: beneficial therapy effects].

Der Urologe. Ausg. A

[Article in German]
L A Kluth, M Rink, S A Ahyai, M Fisch, S F Shariat, P Dahm

Affiliations

  1. Klinik für Urologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.

PMID: 23712423 DOI: 10.1007/s00120-013-3144-2

Abstract

Randomized controlled trials (RCTs) stopped prematurely for beneficial therapy effects are becoming increasingly more prevalent in the urological literature and often receive great attention in the public and medical media. Urologists who practice evidence-based medicine should be aware of the potential bias and the different reasons why and how early termination of RCTs can and will affect the results. This review provides insights into the challenges clinical urologists face by interpreting the results of prematurely terminated RCTs.

References

  1. JAMA. 2005 Nov 2;294(17):2203-9 - PubMed
  2. BJU Int. 2005 Dec;96(9):1241-6 - PubMed
  3. N Engl J Med. 2001 Nov 8;345(19):1359-67 - PubMed
  4. JAMA. 2010 Mar 24;303(12):1180-7 - PubMed
  5. N Engl J Med. 2011 May 26;364(21):1995-2005 - PubMed
  6. BJU Int. 2010 Jan;105(1):4-5 - PubMed
  7. J Clin Epidemiol. 2011 Apr;64(4):383-94 - PubMed
  8. N Engl J Med. 1999 Dec 9;341(24):1789-94 - PubMed
  9. Control Clin Trials. 1984 Dec;5(4):348-61 - PubMed

MeSH terms

Publication Types